This segment focuses on the research, development, and clinical trials of novel therapeutics for various cancers. Aileron's primary focus is on ALRN-6924, a chemoprotective agent designed to protect healthy cells from the toxic effects of chemotherapy. Research and development activities include Phase 1, 2a, and 1b clinical trials for solid tumors, lymphoma, acute myeloid leukemia (AML), and advanced myelodysplastic syndrome (MDS). The company utilizes advanced methodologies in drug discovery and clinical trial design to improve patient outcomes. The segment addresses significant unmet needs in cancer treatment by reducing chemotherapy-induced side effects and improving patient quality of life. Aileron's market positioning is based on its unique approach to chemoprotection, offering a potential advantage over traditional cancer treatments. Future opportunities include expanding the application of ALRN-6924 to other cancer types and combination therapies. Regulatory and clinical aspects involve navigating FDA approval processes and conducting rigorous clinical trials. Partnerships with institutions like Dana-Farber Cancer Institute and Pfizer support the segment's activities.